Seattle Institute for Biomedical and Clinical Research

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Seattle Institute for Biomedical and Clinical Research sits in the top decile of US sponsors by registered trial count (#415 of 15,742 sponsors by registered trial count).

43 total trials 6 currently recruiting 29 completed early-phase tilt top decile by trial count

Seattle Institute for Biomedical and Clinical Research: 43 sponsored US clinical trials, 6 recruiting.

Seattle Institute for Biomedical and Clinical Research sponsors 43 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 29 completed. 5 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypogonadism, Male, with 2 trials.

Top-decile sponsor footprint

Seattle Institute for Biomedical and Clinical Research ranks in the top decile of sponsors by registered trial count (#415 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 59/100

29 of 33 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

43 total, page 1 of 1

RECRUITING NA

Automatic Prosthetic Foot Stiffness Modulation to Improve Balance

NCT06711588

RECRUITING NA

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

NCT06390345

RECRUITING NA

A Prosthetic Foot Test-Drive Strategy for Improving Stability in Veterans With Leg Amputations

NCT05473065

RECRUITING NA

Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD

NCT05718102

RECRUITING Phase 2

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

NCT04049331

RECRUITING Phase 2

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

NCT04301765

ACTIVE NOT RECRUITING NA

Efficacy of Virtual Warrior Renew Therapy for Veterans Who Experienced Military Sexual Trauma

NCT05776719

ACTIVE NOT RECRUITING NA

Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV

NCT04505371

ACTIVE NOT RECRUITING

Comparing Ankle Fusion to Ankle Replacement

NCT01620541

NOT YET RECRUITING NA

Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults

NCT07507435

COMPLETED NA

High-quality COPD Care for People With Immune Dysfunction Through Proactive E-consults

NCT03856879

COMPLETED NA

Adherence and Perspiration While Wearing Lower Limb Prostheses

NCT03900845

COMPLETED

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

NCT03867357

COMPLETED NA

A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations

NCT03651830

COMPLETED

Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population

NCT03468309

COMPLETED NA

INtervention Study In overweiGHT Patients With COPD

NCT02634268

COMPLETED Phase 4

Prazosin for Post-Concussive Headaches

NCT02965027

TERMINATED Phase 2

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

NCT02985021

COMPLETED Phase 2

Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders

NCT02322047

COMPLETED NA

Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD

NCT02226367

COMPLETED NA

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645

COMPLETED NA

Mindfulness-Based Stress Reduction and the Microbiome

NCT01619384

COMPLETED NA

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

NCT01126099

COMPLETED NA

Loving-kindness Meditation for Posttraumatic Stress Disorder (PTSD)

NCT01607632

COMPLETED Phase 2

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

NCT01518972

COMPLETED NA

Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

NCT00990106

COMPLETED NA

Reducing Alcohol Use & Post-traumatic Stress Disorder (PTSD) With Cognitive Restructuring & Experiential Acceptance

NCT00760994

COMPLETED NA

Mindfulness Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study

NCT00880152

COMPLETED NA

Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data

NCT00880256

COMPLETED NA

Quetiapine for the Reduction of Cocaine Use

NCT00631748

COMPLETED Phase 2

Study of the Medication Prazosin for Alcohol Dependence

NCT00762710

COMPLETED NA

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

NCT00512070

COMPLETED Phase 2

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

NCT00284206

TERMINATED Phase 4

Efficacy of Galantamine to Treat Schizophrenia

NCT00232349

COMPLETED Phase 2

Cognitive Effects of Aerobic Exercise for MCI Adults

NCT00220467

COMPLETED Phase 2

Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms

NCT00202514

COMPLETED Phase 2

Cognitive Effects of Aerobic Exercise for IGT Adults

NCT00220441

TERMINATED NA

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

NCT00202449

COMPLETED Phase 4

Quetiapine for Cocaine Use and Cravings

NCT00232336

TERMINATED NA

Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

NCT00183430

COMPLETED Phase 2

The Effect of H. Pylori Infection on Iron Metabolism

NCT00202488

COMPLETED Phase 4

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

NCT00303277

COMPLETED Phase 3

Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

NCT00007189

What is open in the Seattle Institute for Biomedical and Clinical Research pipeline

6 recruiting of 43 indexed (14% open); 29 completed (67%).

Phase mix: 5 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Hypogonadism, Male (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Seattle Institute for Biomedical and Clinical Research: open-pipeline peers nationwide

Peers matched on 43 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Seattle Institute for Biomedical and Clinical Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15%20%25% Total trials Recruiting share Seattle Institute for Biomedical and Clinical ResearchAtlantic Health SystemCumberland PharmaceuticalsLahey ClinicOctapharmaUniversity of Illinois at Urbana-ChampaignUniversity of PennsylvaniaJohns Hopkins Bloomberg School of Public HealthMilton S. Hershey Medical Center
Seattle Institute for Biomedical and Clinical Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Seattle Institute for Biomedical and Clinical Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 43 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Seattle Institute for Biomedical and Clinical Research page

43 registered trials is a research-attention snapshot, not an endorsement of Seattle Institute for Biomedical and Clinical Research or any single study.

  • 6 of Seattle Institute for Biomedical and Clinical Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hypogonadism, Male is the condition Seattle Institute for Biomedical and Clinical Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypogonadism, Male trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Seattle Institute for Biomedical and Clinical Research pipeline card: 43 registered trials from official public datasets.Report a data error.